מקורות ספרות
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer Paik et al. J Clin Oncol. 2006;24:3726-3734
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Albain KS et al. Lancet Oncol. 2009 Dec: 1-11
- Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Petkov VI et al. npj Breast Cancer. 2016: 2:1-9
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Sparano J.A. et al. N Engl J Med. 2018 Jun 1-11
- Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors. Tang et al. JCO 2011. 29(33): 4365–4372
- Use of the 21-gene Oncotype DX® Breast Recurrence Score® assay in the neoadjuvant treatment setting. Robidoux A et al. The Breast, 2017.32(1):S80
- Abstract PD5-03: TransNEOS: Validation of the oncotype DX recurrence score (RS) testing core needle biopsy samples from NEOS as predictor of clinical response to neoadjuvant endocrine therapy for postmenopausal estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer patients. Iwata H et al. Cancer Research. 2018. 78(4 Supplement):PD5-03-PD5-03
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Krop I et al. JCO 2017. 20;35(24):2838-2847
- The NCCN Guidelines, Version 1.2018. 03/2018
- AJCC Cancer Staging Manual. 8th Edition, Part XI, Breast. 589-636
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Sparano et al. N Engl J Med 2018; 379:111-121.
- Breast Cancer-specific Mortality in Patients With Node-negative and Node-positive Breast Cancer Guided by the 21-gene Assay: A SEER-Genomic Population-based Study. Hortobagyi et al. SABCS Dec 2018.
- Le, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, NEJM 2015
- Le, et al. PD-1 blockade in mismatch repair deficient noncolorectal gastrointestinal cancers, Science June 2017.
- Jones et al. Personalized genomic analyses for cancer mutation discovery and interpretation, Science Translational Medicine April 2015
- M et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. New England Journal of medicine 2017
- Rabizadeh S, Garner C, Sanborn JZ, et al. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget 2018
- Odegaard, J. I. et al.Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clinical Cancer Research, Published Online 24 April 2018
- Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell- Free Circulating Tumor DNA. PLoS One 2015;10:e0140712.
